

Donald W Light

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11960413/publications.pdf>

Version: 2024-02-01

69
papers

2,055
citations

279798

23
h-index

254184

43
g-index

76
all docs

76
docs citations

76
times ranked

1469
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Pharmaceuticals as a market for "lemons": Theory and practice. <i>Social Science and Medicine</i> , 2021, 268, 113368. | 3.8 | 8 |
| 2 | The costs of coronavirus vaccines and their pricing. <i>Journal of the Royal Society of Medicine</i> , 2021, 114, 502-504. | 2.0 | 31 |
| 3 | Addressing Health Care Disparities: A Radical Perspective and Proposal. <i>Frontiers in Sociology</i> , 2020, 5, 29. | 2.0 | 3 |
| 4 | The "American (cancer) patients first" plan to reduce drug prices: A critical assessment. <i>American Journal of Hematology</i> , 2018, 93, 1444-1450. | 4.1 | 3 |
| 5 | Pricing pharmaceutical drugs in the USA. , 2018, , 63-79. | | 3 |
| 6 | Manufacturing costs of HPV vaccines for developing countries. <i>Vaccine</i> , 2016, 34, 5984-5989. | 3.8 | 50 |
| 7 | Why do cancer drugs get such an easy ride?. <i>BMJ</i> , The, 2015, 350, h2068-h2068. | 6.0 | 36 |
| 8 | Good Pharma. , 2015, , . | | 9 |
| 9 | The FDA's new clothes. <i>BMJ</i> , The, 2015, 351, h4897. | 6.0 | 11 |
| 10 | Pioneering Ethical Trials for Integrated Research. , 2015, , 133-157. | | 0 |
| 11 | International Campaigns against Harmful Regulations and Practices. , 2015, , 179-196. | | 0 |
| 12 | Science-Based Initiatives against Dangerous or Useless Drugs. , 2015, , 161-178. | | 0 |
| 13 | Good Science for Good Pharma: A Public-Health Model. , 2015, , 197-217. | | 0 |
| 14 | Pharmaceutical Sales Representatives and Patient Safety. <i>Journal of General Internal Medicine</i> , 2013, 28, 1394-1394. | 2.6 | 1 |
| 15 | Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs. <i>Journal of Law, Medicine and Ethics</i> , 2013, 41, 590-600. | 0.9 | 112 |
| 16 | Market spiral pricing of cancer drugs. <i>Cancer</i> , 2013, 119, 3900-3902. | 4.1 | 77 |
| 17 | Categorical inequality, institutional ambivalence, and permanently failing institutions: the case of immigrants and barriers to health care in America. <i>Ethnic and Racial Studies</i> , 2012, 35, 23-39. | 2.3 | 16 |
| 18 | Life on the edge: immigrants confront the American health system. <i>Ethnic and Racial Studies</i> , 2012, 35, 3-22. | 2.3 | 82 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Pharmaceutical research and development: what do we get for all that money?. <i>BMJ, The</i> , 2012, 345, e4348-e4348. | 6.0 | 168 |
| 20 | Demythologizing the high costs of pharmaceutical research. <i>BioSocieties</i> , 2011, 6, 34-50. | 1.3 | 155 |
| 21 | Historical and comparative reflections on the U.S. national health insurance reforms. <i>Social Science and Medicine</i> , 2011, 72, 129-132. | 3.8 | 21 |
| 22 | Reflections on commissioning and the English coalition government NHS reforms. <i>Social Science and Medicine</i> , 2011, 72, 821-822. | 3.8 | 4 |
| 23 | Saving the pneumococcal AMC and GAVI. <i>Hum Vaccin</i> , 2011, 7, 138-141. | 2.4 | 8 |
| 24 | Exaggerating The Benefits Of The "Decade Of Vaccines". <i>Health Affairs</i> , 2011, 30, 2026-2026. | 5.2 | 1 |
| 25 | Longer Exclusivity Does Not Guarantee Better Drugs. <i>Health Affairs</i> , 2011, 30, 798-798. | 5.2 | 0 |
| 26 | GAVI's Advance Market Commitment. <i>Lancet, The</i> , 2010, 375, 638. | 13.7 | 14 |
| 27 | Policy Making on Data Exclusivity in the European Union: From Industrial Interests to Legal Realities. <i>Journal of Health Politics, Policy and Law</i> , 2009, 34, 979-1010. | 1.9 | 21 |
| 28 | Estimated research and development costs of rotavirus vaccines. <i>Vaccine</i> , 2009, 27, 6627-6633. | 3.8 | 37 |
| 29 | Globalizing Restricted and Segmented Markets: Challenges to Theory and Values in Economic Sociology. <i>Annals of the American Academy of Political and Social Science</i> , 2007, 610, 232-245. | 1.6 | 8 |
| 30 | Misleading Congress about Drug Development. <i>Journal of Health Politics, Policy and Law</i> , 2007, 32, 895-913. | 1.9 | 11 |
| 31 | What's So Great About Newness?. <i>Health Affairs</i> , 2007, 26, 1793-1793. | 5.2 | 2 |
| 32 | Is G8 putting profits before the world's poorest children?. <i>Lancet, The</i> , 2007, 370, 297-298. | 13.7 | 13 |
| 33 | A Conservative Case for Universal Access to Health Care. <i>Hastings Center Report</i> , 2006, 36, 36-45. | 1.0 | 26 |
| 34 | Be Clear About Managed Care to Get Clear About Doctor-Patient Relations. <i>American Journal of Bioethics</i> , 2006, 6, 35-36. | 0.9 | 5 |
| 35 | Analysis from the grassroots: how does pollution exposure vary by race and income?. <i>Journal of Health Politics, Policy and Law</i> , 2006, 31, 1151-63. | 1.9 | 0 |
| 36 | Making Practical Markets for Vaccines. <i>PLoS Medicine</i> , 2005, 2, e271. | 8.4 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Foreign free riders and the high price of US medicines. <i>BMJ: British Medical Journal</i> , 2005, 331, 958-960. | 2.3 | 59 |
| 38 | Extraordinary claims require extraordinary evidence. <i>Journal of Health Economics</i> , 2005, 24, 1030-1033. | 2.7 | 52 |
| 39 | Setting the record straight in the reply by DiMasi, Hansen and Grabowski. <i>Journal of Health Economics</i> , 2005, 24, 1045-1048. | 2.7 | 17 |
| 40 | A conservative case for universal health insurance. <i>New Jersey Medicine: the Journal of the Medical Society of New Jersey</i> , 2005, 102, 35-7. | 0.0 | 0 |
| 41 | Improving medical practice and the economy through universal health insurance. <i>New Jersey Medicine: the Journal of the Medical Society of New Jersey</i> , 2005, 102, 39-44. | 0.0 | 0 |
| 42 | Measuring Fairness: An Opportunity for Empirical Ethics. <i>American Journal of Bioethics</i> , 2004, 4, 105-106. | 0.9 | 1 |
| 43 | Ironies of success: a new history of the American health care "system". <i>Journal of Health and Social Behavior</i> , 2004, 45 Suppl, 1-24. | 4.8 | 4 |
| 44 | No Exit and the Organization of Voice in Biotechnology and Pharmaceuticals. <i>Journal of Health Politics, Policy and Law</i> , 2003, 28, 473-508. | 1.9 | 11 |
| 45 | Universal Health Care: Lessons From the British Experience. <i>American Journal of Public Health</i> , 2003, 93, 25-30. | 2.7 | 50 |
| 46 | Introduction: A sociological perspective on rationing: power, rhetoric and situated practices. <i>Sociology of Health and Illness</i> , 2001, 23, 551-569. | 2.1 | 40 |
| 47 | Comparative institutional response to economic policy managed competition and governmentality. <i>Social Science and Medicine</i> , 2001, 52, 1151-1166. | 3.8 | 41 |
| 48 | Managed competition, governmentality and institutional response in the United Kingdom. <i>Social Science and Medicine</i> , 2001, 52, 1167-1181. | 3.8 | 66 |
| 49 | Cost Containment and the Backdraft of Competition Policies. <i>International Journal of Health Services</i> , 2001, 31, 681-708. | 2.5 | 13 |
| 50 | Good Managed Care Needs Universal Health Insurance. <i>Annals of Internal Medicine</i> , 1999, 130, 686. | 3.9 | 18 |
| 51 | Commentary: The New Paternalism. <i>Medical Care Research and Review</i> , 1999, 56, 141-144. | 2.1 | 1 |
| 52 | Benchmarks of Fairness: A Moral Framework for Assessing Equity. <i>International Journal of Health Services</i> , 1999, 29, 853-869. | 2.5 | 15 |
| 53 | Managed Care in a New Key: Britain's Strategies for the 1990s. <i>International Journal of Health Services</i> , 1998, 28, 427-444. | 2.5 | 14 |
| 54 | From Managed Competition to Managed Cooperation: Theory and Lessons from the British Experience. <i>Milbank Quarterly</i> , 1997, 75, 297-341. | 4.4 | 77 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | The Rhetorics and Realities of Community Health Care: The Limits of Countervailing Powers to Meet the Health Care Needs of the Twenty-First Century. <i>Journal of Health Politics, Policy and Law</i> , 1997, 22, 105-145. | 1.9 | 84 |
| 56 | Homo Economicus: escaping the traps of managed competition. <i>European Journal of Public Health</i> , 1995, 5, 145-154. | 0.3 | 39 |
| 57 | Life, Death, and the Insurance Companies. <i>New England Journal of Medicine</i> , 1994, 330, 498-500. | 27.0 | 29 |
| 58 | Escaping the traps of postwar Western medicine. <i>European Journal of Public Health</i> , 1993, 3, 281-289. | 0.3 | 19 |
| 59 | The Practice and Ethics of Risk-Rated Health Insurance. <i>JAMA - Journal of the American Medical Association</i> , 1992, 267, 2503. | 7.4 | 83 |
| 60 | Uncertainty and Professional Work: Perceptions of Physicians in Clinical Practice. <i>American Journal of Sociology</i> , 1992, 97, 1022-1051. | 0.5 | 130 |
| 61 | Other Side Of British Health Reform. <i>Health Affairs</i> , 1992, 11, 280-281. | 5.2 | 0 |
| 62 | Equity and efficiency in health care. <i>Social Science and Medicine</i> , 1992, 35, 465-469. | 3.8 | 17 |
| 63 | Professionalism as a Countervailing Power. <i>Journal of Health Politics, Policy and Law</i> , 1991, 16, 499.1-506. | 1.9 | 23 |
| 64 | Toward a New Sociology of Medical Education. <i>Journal of Health and Social Behavior</i> , 1988, 29, 307. | 4.8 | 50 |
| 65 | Corporate Medicine for Profit. <i>Scientific American</i> , 1986, 255, 38-45. | 1.0 | 77 |
| 66 | Values and Structure in the German Health Care Systems. <i>The Milbank Memorial Fund Quarterly Health and Society</i> , 1985, 63, 615. | 0.8 | 22 |
| 67 | Is Competition Bad?. <i>New England Journal of Medicine</i> , 1983, 309, 1315-1319. | 27.0 | 10 |
| 68 | Pharmaceutical Research and Development: What Do We Get for All that Money?. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 5 |
| 69 | The Sociological Character of Health-Care Markets. , 0, , 394-408. | | 33 |